MAP Pharmaceuticals Reaches Agreement With FDA On Special Protocol Assessment For MAP0004 Phase 3 Cl

CommentPost ArticleSave to My ArticlesList ArticlesRandom Article

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, announced that it has completed the special protocol assessment (SPA) process with the U.S. Food and Drug Administration (FDA) for the first Phase 3 clinical trial of its MAP0004 product candidate, and has reached agreement with the Agency on the design of the protocol. The study, if successful, could support the potential approval of MAP0004 as a treatment for migraine.